
Soligenix Completes Enrollment for Interim Analysis in Phase 3 FLASH2 Study of HyBryte
Soligenix has completed enrollment for the interim analysis of its Phase 3 FLASH2 study evaluating HyBryte in cutaneous T-cell lymphoma, with a 48 percent blinded response rate exceeding expectations and potential regulatory approval implications.
Read full story























